Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production yield by 400%. The company…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of…
As July came to an end, the United States reached an undesirable milestone: exceeding the total number of confirmed cases…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious diseases spread, and policymakers don’t seem to…
Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months from the time they are…
The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The leadership change comes as the…
Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization…
For a long time, scientists have wondered why many individuals that have several risk factors linked to cancer development never develop the disease while some…
Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine,…
Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision oncology becomes increasingly dependent on…